Henan Cancer Hospital
🇨🇳China
- Country
- 🇨🇳China
- Ownership
- Private
- Established
- 1977-01-01
- Employees
- -
- Market Cap
- -
QL1706 for the Neoadjuvant Treatment of HR+/HER2- Breast Cancer
Phase 2
Not yet recruiting
- Conditions
- Breast CancerHR+/HER2- Breast Cancer
- Interventions
- Drug: Nab-PE
- First Posted Date
- 2025-05-13
- Last Posted Date
- 2025-05-13
- Lead Sponsor
- Henan Cancer Hospital
- Target Recruit Count
- 238
- Registration Number
- NCT06967103
Organoid-guided Personalized Treatment of Pleural Effusion
Recruiting
- Conditions
- Lung Cancer
- First Posted Date
- 2025-05-06
- Last Posted Date
- 2025-05-06
- Lead Sponsor
- Henan Cancer Hospital
- Target Recruit Count
- 20
- Registration Number
- NCT06959173
- Locations
- 🇨🇳
Henan cancer hospital, Zhengzhou, Henan, China
Clinical Trial of HRS-4642 Plus SHR-A2102 in Patients With Advanced Solid Tumors
Phase 1
Not yet recruiting
- Conditions
- Solid Tumors
- Interventions
- Drug: SHR-A2102+HRS-4642
- First Posted Date
- 2025-05-02
- Last Posted Date
- 2025-05-02
- Lead Sponsor
- Henan Cancer Hospital
- Target Recruit Count
- 32
- Registration Number
- NCT06955390
- Locations
- 🇨🇳
Henan Cancer Hospital, Zhengzhou, Henan, China
A Clinical Trial of Furmonertinib Combined With Anlotinib as First-line Treatment for Advanced NSCLC With EGFR-sensitive Mutations and Brain Metastasis
Phase 2
Recruiting
- Conditions
- NSCLC
- Interventions
- Drug: furmonertinib combined with anlotinib
- First Posted Date
- 2025-04-25
- Last Posted Date
- 2025-04-25
- Lead Sponsor
- Henan Cancer Hospital
- Target Recruit Count
- 146
- Registration Number
- NCT06945705
- Locations
- 🇨🇳
Henan Cancer Hospital, Zhengzhou, China
The Efficacy of Oral Cryotherapy in Preventing TROP2-ADC-Induced Oral Mucositis in Patients With Advanced Breast Cancer
Not Applicable
Not yet recruiting
- Conditions
- Advanced or Metastatic Breast Cancer
- First Posted Date
- 2025-04-18
- Last Posted Date
- 2025-04-18
- Lead Sponsor
- Henan Cancer Hospital
- Target Recruit Count
- 124
- Registration Number
- NCT06934733
- Locations
- 🇨🇳
Henan Cancer Hospital, Zhengzhou, Henan, China
SHR-A1811 Plus Pertuzumab in the Neoadjuvant Treatment of HER2 Positive BC
Phase 2
Not yet recruiting
- Conditions
- Breast Cancer Early Stage Breast Cancer (Stage 1-3)
- Interventions
- Drug: Albumin-Paclitaxel
- First Posted Date
- 2025-04-15
- Last Posted Date
- 2025-04-15
- Lead Sponsor
- Henan Cancer Hospital
- Target Recruit Count
- 180
- Registration Number
- NCT06927180
- Locations
- 🇨🇳
Henan Cancer Hospital, Zhengzhou, Henan, China
Real World Study of Oxycodone/Naloxone Sustained-Release Tablets (Mimeixin) for Patients With Severe Cancer Pain
Phase 4
Not yet recruiting
- Conditions
- Opioid-Induced ConstipationPain Cancer
- Interventions
- Drug: Oxycodone Hydrochloride and Naloxone Hydrochloride Sustained-release Tablets
- First Posted Date
- 2025-03-27
- Last Posted Date
- 2025-03-27
- Lead Sponsor
- Henan Cancer Hospital
- Target Recruit Count
- 203
- Registration Number
- NCT06897917
- Locations
- 🇨🇳
Henan Cancer Hospital, Zhengzhou, Henan, China
A Study of SHR-A1811 and Fulvestrant, With or Without HS-10352, in Locally Advanced or Metastatic Breast Cancer Patients
Phase 1
Not yet recruiting
- Conditions
- Breast CancerLocally Advanced or Metastatic Breast Cancer
- Interventions
- Drug: SHR-A1811+fulvestrantDrug: SHR-A1811 +Fulvestrant +HS-10352Drug: SHR-A1811+ FulvestrantDrug: SHR-A1811+ Fulvestrant+HS-10352
- First Posted Date
- 2025-03-25
- Last Posted Date
- 2025-03-26
- Lead Sponsor
- Henan Cancer Hospital
- Target Recruit Count
- 52
- Registration Number
- NCT06788197
Prospective Phase II Clinical Study of Neoadjuvant Chemoradiotherapy Combined With PD-1/PD-L1 Inhibitors in the Treatment of Locally Advanced Resectable Esophageal Squamous Cell Carcinoma
Phase 2
Active, not recruiting
- Conditions
- Esophageal Malignant Neoplasm Primary
- First Posted Date
- 2025-03-21
- Last Posted Date
- 2025-03-21
- Lead Sponsor
- Henan Cancer Hospital
- Target Recruit Count
- 30
- Registration Number
- NCT06888531
- Locations
- 🇨🇳
Henan Cancer Hospital, Zhengzhou, Henan, China
Serplulimab Combined with Chemotherapy for Early-stage HR+/HER2- Breast Cancer
Phase 2
Not yet recruiting
- Conditions
- HR+/HER2- Breast Cancer
- Interventions
- First Posted Date
- 2025-03-06
- Last Posted Date
- 2025-03-06
- Lead Sponsor
- Henan Cancer Hospital
- Target Recruit Count
- 357
- Registration Number
- NCT06860529
© Copyright 2025. All Rights Reserved by MedPath